SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression

Zhang, Hangyu; Liu, Changgang; Wang, Xinbo; Wang, Yongfang; Zheng, Jie

doi:10.7150/jca.52426



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(8):2412-2421. doi:10.7150/jca.52426 This issue Cite

Research Paper

SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression

Hangyu Zhang¹, Changgang Liu¹, Xinbo Wang², Yongfang Wang¹, Jie Zheng^1,3✉

1. Department of Diagnostic Pathology, School of Basic Medical Sciences, Weifang Medical University, Shandong Province, China.
2. Department of Surgical Oncology, Weifang People's Hospital, Weifang Medical University, Shandong Province, China.
3. Key Lab of Neurological Disease and Regeneration & Repair, Weifang Medical University, Shandong Province, China.

Citation:

Zhang H, Liu C, Wang X, Wang Y, Zheng J. SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression. J Cancer 2021; 12(8):2412-2421. doi:10.7150/jca.52426. https://www.jcancer.org/v12p2412.htm

Other styles

Abstract

Scavenger receptor class A member 5 (SCARA5) has been reported to be implicated in several types of cancer. However, its biological roles and mechanism of SCARA5 in gastric cancer (GC) have not been elucidated. In the present study, SCARA5 expression was found to be downregulated in GC which was associated with promoter methylation. The protein level of SCARA5 was negatively associated with aggressive clinicopathological characteristics, as well as poor prognosis. Moreover, SCARA5 overexpression markedly suppressed the growth, migration and invasion of GC cell lines in vitro. Furthermore, upregulation of SCARA5 inhibited gastric tumor growth and metastasis in a xenograft model. Mechanistic analysis revealed that SCARA5 suppressed the migration and invasion of GC cells via inhibiting epithelial-mesenchymal transition (EMT) and inactivating MMP-2 and MMP-9. Taken together, these results demonstrated that SCARA5 might play vital roles in the GC genesis and progression and could serve as a potential biomarker for diagnosis and therapeutic target of GC.

Keywords: Gastric cancer, SCARA5, proliferation, migration and invasion, EMT

Citation styles

APA

Zhang, H., Liu, C., Wang, X., Wang, Y., Zheng, J. (2021). SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression. Journal of Cancer, 12(8), 2412-2421. https://doi.org/10.7150/jca.52426.

ACS

Zhang, H.; Liu, C.; Wang, X.; Wang, Y.; Zheng, J. SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression. J. Cancer 2021, 12 (8), 2412-2421. DOI: 10.7150/jca.52426.

NLM

CSE

Zhang H, Liu C, Wang X, Wang Y, Zheng J. 2021. SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression. J Cancer. 12(8):2412-2421.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.